Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
Status:
Terminated
Trial end date:
2021-04-19
Target enrollment:
Participant gender:
Summary
This study is a phase II, parallel, prospective, randomized, double-blind, placebo controlled
trial. The present study will aim to address the efficacy and safety of acute administration
of triiodothyronine on ICU patients diagnosed with pulmonary infection due to COVID-19 and
require mechanical respiratory support or ECMO.